Cheryl Reicin
Canada Guide 2024
Band 1 : Life Sciences: Corporate/Commercial
Band 1
About
Provided by Cheryl Reicin
Practice Areas
Cheryl advises the industry’s largest investors and most innovative startups on highly complex transactions worldwide. With an international reputation for quality and helping clients advance their strategies, Cheryl combines deep knowledge of the market with a business-minded practical approach.
. She represents the entire spectrum of biotech, medical device and health technology companies, from start-ups to large public companies, as well as venture capitalists, investment banks and academic medical centers.
Cheryl is widely recognized for her long track record of helping life sciences companies at all stages formulate and evolve their domestic and international growth strategies, source capital, and develop and optimize their corporate and tax structures. Cheryl has extensive experience advising on venture and later-stage financings, IPOs, M&A, licensing transactions and joint ventures or alliances with strategic partners.
Cheryl has been named WXN’s Canada’s Top 100 Most Powerful Women four times and inducted into its Hall of Fame. She has been repeatedly recognized by LMG Life Sciences as the Canadian Finance & Corporate Attorney of the Year.
Articles, highlights and press releases
7 items provided by Mintz
Life sciences and real estate: new opportunities
From R&D spaces to manufacturing sites, the exponential growth of Canada’s life sciences industry is revealing new opportunities for investors to diversify their portfolios. Here we explore the current environment, costs, risks & other considerations for developers, investors, landlords & tenants.
Accelerated growth in Canada’s life sciences industry
From drug discovery to diagnostics and biotech, the Canadian life sciences industry is becoming increasingly versatile and dynamic. Investor and consumer interest in the industry continues to rise, and all indications are that the positive momentum in the industry is likely to continue.
Emerging Companies in Canada: Data and Digital Technology and Life Sciences
The growth of Canada’s emerging company and tech sector has been on a path of acceleration. We are also seeing increased foreign investment into the industry, particularly from America. The tech sector’s presence is being felt nationwide. Here we discuss key growth areas to watch moving forwards.
The past year saw the biotech industry experience phenomenal growth, with capital deployment levels far greater than ever before and dealmaking occurring in both public and private markets. We predict further upward progress and chart the drivers and trends of the biotech sector in this article.
Torys Video: Financing life sciences on both sides of the border
The pandemic has been a turning point for investment in life sciences. In this video, our team discusses financing for life science companies, along with the advantages that Canada’s multi-jurisdictional disclosure system provides, and how COVID has highlighted the importance of this practice area.
Torys Quarterly: Pandemic’s mandate to innovate a turning point for life sciences
Life sciences companies have challenging business models. The silver lining is that this pandemic has shone a light on the importance of medical and health innovation.
Torys Business Brief: A turning point for Canada’s life sciences
What lessons can be learned from the pandemic for the life sciences industry? Hear from Eileen McMahon and Cheryl Reicin and researcher Dr. Shaf Keshavjee
Life sciences and real estate: new opportunities
From R&D spaces to manufacturing sites, the exponential growth of Canada’s life sciences industry is revealing new opportunities for investors to diversify their portfolios. Here we explore the current environment, costs, risks & other considerations for developers, investors, landlords & tenants.
Accelerated growth in Canada’s life sciences industry
From drug discovery to diagnostics and biotech, the Canadian life sciences industry is becoming increasingly versatile and dynamic. Investor and consumer interest in the industry continues to rise, and all indications are that the positive momentum in the industry is likely to continue.
Emerging Companies in Canada: Data and Digital Technology and Life Sciences
The growth of Canada’s emerging company and tech sector has been on a path of acceleration. We are also seeing increased foreign investment into the industry, particularly from America. The tech sector’s presence is being felt nationwide. Here we discuss key growth areas to watch moving forwards.
The past year saw the biotech industry experience phenomenal growth, with capital deployment levels far greater than ever before and dealmaking occurring in both public and private markets. We predict further upward progress and chart the drivers and trends of the biotech sector in this article.
Torys Video: Financing life sciences on both sides of the border
The pandemic has been a turning point for investment in life sciences. In this video, our team discusses financing for life science companies, along with the advantages that Canada’s multi-jurisdictional disclosure system provides, and how COVID has highlighted the importance of this practice area.
Torys Quarterly: Pandemic’s mandate to innovate a turning point for life sciences
Life sciences companies have challenging business models. The silver lining is that this pandemic has shone a light on the importance of medical and health innovation.
Torys Business Brief: A turning point for Canada’s life sciences
What lessons can be learned from the pandemic for the life sciences industry? Hear from Eileen McMahon and Cheryl Reicin and researcher Dr. Shaf Keshavjee